Table 2

Number of events, person years, crude and standardised incidence rates and HRs, for all cancers other than NMSC, and for cancer sites where at least five incident events were observed in the JAK cohort, in Swedish patients with RA treated with JAKi, non-TNFi bDMARDs or TNFi

CohortEventsPerson years, noCrude incidence rate per 1000 person-yearsStandardised incidence rate per 1000 person-yearsFully adjusted HR*
All cancers other than NMSC
 All JAKi3839969.58.30.94 (0.65 to 1.38)
  Tofacitinib879310.111.21.08 (0.52 to 2.24)
  Baricitinib3031879.48.00.92 (0.61 to 1.38)
  Non-TNFi bDMARD†14111 05112.810.51.12 (0.88 to 1.43)
  TNFi21321 12210.110.11.0 (Reference)
  General population1245128 2249.79.2n/a
 All JAKi59395414.912.91.39 (1.01 to 1.91)
  Tofacitinib1178114.114.91.56 (0.83 to 2.92)
  Baricitinib48315715.212.51.37 (0.97 to 1.92)
  Non-TNFi bDMARD†12611 02711.49.01.00 (0.78 to 1.28)
  TNFi18921 0839.09.01.0 (Reference)
  General population852128 6306.66.2n/a
Breast cancer
 All JAKi740141.71.60.73 (0.29 to 1.86)
  Baricitinib632011.91.70.77 (0.29 to 2.06)
  Non-TNFi bDMARD†2311 1972.11.90.88 (0.48 to 1.61)
  TNFi4221 3282.02.01.0 (Reference)
  General population262129 6012.02.0n/a
All haematopoietic
 All JAKi640181.51.51.90 (0.70 to 5.16)
  Baricitinib532031.61.61.96 (0.66 to 5.79)
  Non-TNFi bDMARD†1211 2171.10.91.04 (0.48 to 2.25)
  TNFi2221 3591.01.01.0 (Reference)
  General population99129 8540.80.7n/a
Lung cancer
 All JAKi740211.71.51.15 (0.57 to 2.32)
  Baricitinib532061.61.20.98 (0.44 to 2.23)
  Non-TNFi bDMARD†1111 2241.00.70.59 (0.31 to 1.15)
  TNFi3021 3681.41.41.0 (Reference)
  General population111129 9120.90.8n/a
  • Estimated from Cox proportional hazards models. Standardised incidence rate standardised to the age and sex distribution in the TNFi cohort. – is displayed when too few events (<5) were observed.

  • *Fully adjusted HR: adjusted for age, sex, line of therapy, for comorbidities, SES, disease-related factors and with missing categories included for those variables with missing information.

  • †Non-TNFI bDMARD includes rituximab, abatacept, tocilizumab.

  • bDMARD, biological disease-modifying antirheumatic drug; JAKi, Janus kinas inhibitor; n/a, not available; NMSC, non-melanoma skin cancer; RA, rheumatoid arthritis; SES, socioeconomic status; TNFi, tumour necrosis factor inhibitor.